{"id":619279,"date":"2022-09-30T19:20:01","date_gmt":"2022-09-30T19:20:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=619279"},"modified":"2022-09-30T19:20:01","modified_gmt":"2022-09-30T19:20:01","slug":"metastatic-merkel-cell-carcinoma-market-is-projected-to-grow-during-the-forecast-period-202232-incyte-transgene-ocellaris-roche-exelixis-sensei-sotio-biotech-merck-morphogenesis","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/metastatic-merkel-cell-carcinoma-market-is-projected-to-grow-during-the-forecast-period-202232-incyte-transgene-ocellaris-roche-exelixis-sensei-sotio-biotech-merck-morphogenesis_619279.html","title":{"rendered":"Metastatic Merkel Cell Carcinoma Market is Projected to Grow During the Forecast Period (2022-32) | Incyte, Transgene, Ocellaris, Roche, Exelixis, Sensei, SOTIO Biotech, Merck, Morphogenesis"},"content":{"rendered":"
\n
\"Metastatic<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight\u2019s assessment, globally, about 13+ key pharma and biotech companies are working in the Metastatic Merkel Cell Carcinoma therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types.<\/div>\n

As per DelveInsight, the Metastatic Merkel Cell Carcinoma Market Size is anticipated to increase in the coming years owing to the rise in the number of incident population of Metastatic Merkel Cell Carcinoma patients in the 7MM. Extensive R&D activities by academia and industries and the expected launch of therapies will also fuel the market’s growth. <\/em><\/p>\n

Several of the therapies are in development by major pharma giants and are expected to launch in the coming years. Currently, Incyte<\/strong> has its Metastatic Merkel Cell Carcinoma drug candidates in the most advanced stage of clinical development.<\/em><\/p>\n

DelveInsight’s “Metastatic Merkel Cell Carcinoma Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Metastatic Merkel Cell Carcinoma Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n

The Metastatic Merkel Cell Carcinoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Metastatic<\/p>\n

Metastatic Merkel Cell Carcinoma: An Overview<\/strong><\/p>\n

Merkel Cell Carcinoma (MCC)<\/strong> is a rare, highly aggressive neuroendocrine cutaneous neoplasm with a variable clinical presentation. It is a predominantly dermal-based lesion composed of monotonous small round cells with scanty cytoplasm, often difficult to differentiate from small round cell tumors, metastatic small cell carcinoma, blastic hematologic malignancies, and melanoma.<\/p>\n

It is caused by ultraviolet (UV) light exposure, infection with the HIV virus, autoimmune diseases (rheumatoid arthritis), and certain malignancies like chronic lymphocytic leukemia or lymphomas, which can profoundly suppress the immune system and may act as a causative agent in MCC. It is also associated with Merkel cell polyomavirus in more than 80% of cases.<\/p>\n

Treatment of stage IV Merkel cell carcinoma may include the following:  Immunotherapy (immune checkpoint inhibitor therapy using avelumab or pembrolizumab)<\/em>. Chemotherapy, surgery, or radiation therapy<\/em> as palliative treatment to relieve symptoms and improve quality of life. <\/p>\n

Metastatic Merkel Cell Carcinoma Market Key Facts<\/strong><\/p>\n